Abstract
Introduction Children with monogenic neurodevelopmental disorders often grow abnormally. Gene-specific growth charts would be useful but require large samples to construct them using the conventional LMS method.
Methods We transformed anthropometry to British 1990 reference z-scores for 328 UK and 264 international probands with ANKRD11, ARID1B, ASXL3, DDX3X, KMT2A or SATB2-related disorders, and modelled mean and standard deviation (SD) of the z-scores as gene-specific linear age trends adjusted for sex. Back-transforming the mean ±2 SD lines provided gene-specific median, 2nd and 98th centiles.
Results The resulting z-score charts look plausible on several counts. Only KMT2A shows a (rising) age trend in median height, while BMI and weight increase in several genes, possibly reflecting population trends. Apart from SATB2 and DDX3X, the gene-specific medians are all below the reference (range 0.1th centile for height KMT2A to 36th centile for BMI ANKRD11). Median OFC shows no age trend, with medians ranging from 10th-30th centile, and ASXL3 lowest, on the 3rd centile. There are no sex differences in 19/24 cases.
Conclusions Our LMSz method produces gene-specific growth charts for rare diseases, an essential clinical tool for paediatric care. We plan to automate it within the DECIPHER platform, enabling availability for all relevant genes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding statement The DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003], a parallel funding partnership between the Wellcome Trust and the Department of Health, and the Wellcome Sanger Institute [grant number WT098051]. This study was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre. The research team acknowledges the support of the National Institute for Health Research, through the Comprehensive Clinical Research Network. JF is funded by the Wellcome Trust [grant number WT223718/Z/21/Z]. This research was funded in whole or in part by the Wellcome Trust. MB is funded by the MRC (MR/V037307/1). For the purpose of open access, the author has applied a CC-BY public copyright licence to any author accepted manuscript version arising from this submission. KL is supported by the National Institute for Health and Care Research Doctoral Research Fellowship 302303. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The DDD study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). All participants gave informed consent, as required by the REC. All published data were de-identified. Specific ethical approval for the growth charts development was given via a DDD Complementary Analysis Proposal Approval (CAP#371). The GenROC study received East Midlands - Nottingham Research Ethics Committee (REC) approval on 15 December 2022 and Health Research Authority approval on 9 February 2023. The ASXL3 Natural History Study, sponsored by Sheffield Children's Hospital and The University of Sheffield (UK) received REC (23/SC/0151) and HRA approval on 2 June 2023. All participants enrolled in the study gave informed consent for anonymised data sharing to allow this collaboration.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
Sequence and variant-level data and phenotypic data for the DDD study data are available from the European Genome-phenome Archive (EGA; https://www.ebi.ac.uk/ega/) with study ID EGAS00001000775. Clinically interpreted variants and associated phenotypes from the DDD study and GenROC study are available through DECIPHER (https://www.deciphergenomics.org/).
